A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
Everolimus has been studied across 16 research domains including 🔬 Oncology, 🛡️ Immunity, 🫘 Kidney, 🧬 Hormones, 🫁 Liver & Detox. The primary research focus is 🔬 Oncology with 41% of studies addressing this area.
The following compounds share molecular targets with Everolimus, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Everolimus is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.